Renaissance Technologies
RLMD icon

Renaissance Technologies’s Relmada Therapeutics RLMD Stock Holding History

Renaissance Technologies’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$400K Sell
57,800
-109,400
-65% -$764K ﹤0.01% 2687
2026
Q1 		$1.16M Sell
167,200
-17,800
-10% -$84.2K ﹤0.01% 2186
2025
Q4 		$894K Buy
185,000
+15,300
+9% +$51.3K ﹤0.01% 2342
2025
Q3 		$341K Buy
169,700
+19,600
+13% +$18.8K ﹤0.01% 2954
2025
Q2 		$90.1K Buy
150,100
+26,000
+21% +$13.3K ﹤0.01% 3319
2025
Q1 		$33.5K Sell
124,100
-40,413
-25% -$13.4K ﹤0.01% 3329
2024
Q4 		$85.5K Buy
164,513
+138,625
+535% +$338K ﹤0.01% 3307
2024
Q3 		$83.9K Sell
25,888
-62,887
-71% -$204K ﹤0.01% 3283
2024
Q2 		$266K Buy
88,775
+53,767
+154% +$195K ﹤0.01% 2953
2024
Q1 		$163K Sell
35,008
-111,881
-76% -$539K ﹤0.01% 3273
2023
Q4 		$608K Buy
146,889
+81,614
+125% +$242K ﹤0.01% 2697
2023
Q3 		$196K Sell
65,275
-67,497
-51% -$200K ﹤0.01% 3098
2023
Q2 		$327K Sell
132,772
-180,403
-58% -$499K ﹤0.01% 3091
2023
Q1 		$708K Buy
313,175
+95,365
+44% +$329K ﹤0.01% 2686
2022
Q4 		$760K Buy
+217,810
New +$1.91M ﹤0.01% 2690
2022
Q1 		– Sell
-14,400
Closed -$324K – 4395
2021
Q4 		$324K Sell
14,400
-1,100
-7% -$24.5K ﹤0.01% 3310
2021
Q3 		$406K Buy
+15,500
New +$415K ﹤0.01% 2967

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies's RLMD Position: Q2 2026 in Review

Renaissance Technologies reduced its Relmada Therapeutics (RLMD) stake by 65% in Q2 2026, selling an estimated $764K and leaving 57,800 shares worth $400K. The position accounts for ﹤0.01% of the portfolio, ranked #2687.

Renaissance Technologies first reported a position in RLMD in Q3 2021 and has held it in 17 quarters since. The position peaked at $1.16M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Renaissance Technologies held 57,800 shares of Relmada Therapeutics worth $400K as of Q2 2026.
  • Renaissance Technologies sold 109,400 Relmada Therapeutics shares in Q2 2026, an estimated $764K.
  • Relmada Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2687 holding.
  • Renaissance Technologies first reported a position in Relmada Therapeutics in Q3 2021 and has held it in 17 quarters since.
  • Renaissance Technologies's Relmada Therapeutics position peaked at $1.16M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.